| Domain | LVNC10-specific fact | Broad LVNC / contextual evidence | Suggested ontology terms | Key citation(s) |
|---|---|---|---|---|
| Identity / identifiers | **Left Ventricular Noncompaction 10 (LVNC10)**; disease-specific MONDO: **0014163**; subtype linked to **MYBPC3** | Broad **left ventricular noncompaction** MONDO: **0018901**; phenotype/trait remains conceptually debated across cardiomyopathies | MONDO:0014163; MONDO:0018901 | (pqac-00000005, pqac-00000020) |
| Synonyms / naming | Numbered subtype name: **Left ventricular noncompaction 10** | LVNC, left ventricular non-compaction, left ventricular hypertrabeculation/noncompaction; recent ESC framing treats LV non-compaction as a **dynamic trait** rather than always a distinct cardiomyopathy | HPO phenotype label suggestion: Left ventricular noncompaction cardiomyopathy | (pqac-00000018, pqac-00000020) |
| Data granularity | Evidence is primarily **aggregated disease-level** and family/cohort literature, not EHR-derived in the retrieved sources | Large cohorts, reviews, and registries dominate current evidence | — | (pqac-00000003, pqac-00000013) |
| Causal gene | **MYBPC3** (myosin binding protein C3) is the mapped causal gene for LVNC10 | MYBPC3 is one of several recurrent LVNC-associated genes; most validated LVNC genes overlap with HCM/DCM architecture | HGNC gene symbol: MYBPC3; Ensembl: ENSG00000134571 | (pqac-00000005, pqac-00000019) |
| Canonical historical variant | Historical human association includes **p.Arg820Trp / R820W** in **MYBPC3** for LVNC10; **current variant classification should be checked in ClinVar before reuse** | MYBPC3 disease can also involve truncating, missense, de novo, deletion, and biallelic combinations with severe phenotypes | HGVS protein suggestion: p.Arg820Trp | (pqac-00000005, pqac-00000001) |
| Inheritance | Most consistent expectation for LVNC10 due to MYBPC3 is **autosomal dominant** with **variable expressivity** and **incomplete penetrance**; severe early disease may occur with **biallelic/compound heterozygous** states | Broad LVNC familial transmission is often AD, but X-linked and maternal patterns also occur in other genetic forms | HPO inheritance term suggestion: Autosomal dominant inheritance | (pqac-00000003, pqac-00000000, pqac-00000001) |
| Principal phenotypes | MYBPC3-related LVNC10 is expected to feature LV noncompaction/hypertrabeculation and may overlap with HCM/DCM phenotypes | Heart failure, ventricular dysfunction, arrhythmia, thromboembolism, sudden cardiac death risk, and ECG abnormalities are recurrent LVNC manifestations | HPO suggestions: Left ventricular noncompaction cardiomyopathy; Arrhythmia; Ventricular tachycardia; Heart failure; Reduced ejection fraction; Sudden cardiac death | (pqac-00000003, pqac-00000004, pqac-00000021) |
| Age at onset / course | **Variable**; can be childhood or adult-onset in heterozygous disease; **early severe onset** reported with biallelic MYBPC3 states | Pediatric to adult presentation occurs broadly; prognosis is heterogeneous | HPO onset suggestions: Childhood onset; Adult onset; Infantile onset (for severe cases) | (pqac-00000000, pqac-00000021) |
| Anatomy | Primary structure affected: **left ventricular myocardium**, especially **apical/trabecular endocardial** regions with noncompacted and compacted layers | Broad LVNC definitions emphasize prominent trabeculae, deep recesses, thin compacted layer | UBERON suggestions: left ventricle; ventricular myocardium; endocardium | (pqac-00000004, pqac-00000019, pqac-00000021) |
| Cell type | Disease-relevant cell type is primarily **cardiomyocyte** | Arrhythmic manifestations imply conduction-system involvement as secondary physiology | CL suggestion: cardiomyocyte | (pqac-00000000, pqac-00000010) |
| Mechanism | MYBPC3-associated mechanism is most consistent with **sarcomeric dysfunction / haploinsufficiency / protein instability**; severe biallelic cases showed marked reduction of MYBPC3 protein in tissue | LVNC broadly reflects overlap of sarcomeric cardiomyopathy biology with abnormal trabeculation/compaction; modifier and developmental influences likely | GO suggestions: sarcomere organization; cardiac muscle contraction; regulation of cardiac muscle cell contraction; ventricular cardiac muscle tissue morphogenesis | (pqac-00000000, pqac-00000001, pqac-00000019) |
| Pathophysiology chain | MYBPC3 variant → altered sarcomeric protein dosage/function → impaired contractile mechanics / myocardial architecture → excessive trabeculation or noncompaction phenotype ± systolic dysfunction/arrhythmia | Broad LVNC may represent either a distinct developmental/noncompaction mechanism or a phenotypic expression of other cardiomyopathies | GO suggestions as above | (pqac-00000000, pqac-00000019, pqac-00000020) |
| Diagnostics | No LVNC10-only diagnostic test identified; diagnosis relies on **clinical imaging + cardiogenetics** | Echo and CMR use NC/C ratio-based criteria; overdiagnosis is a major issue, especially when relying on morphology alone | HPO suggestion: Abnormal left ventricular morphology | (pqac-00000018, pqac-00000019, pqac-00000020) |
| Imaging criteria | LVNC10 uses the same imaging framework as LVNC generally | Typical thresholds cited in retrieved sources: NC/C ratio **>2 to 2.3**; CMR may label up to **15%** of healthy individuals by ratio criteria alone | — | (pqac-00000019, pqac-00000020, pqac-00000008) |
| Genetic testing | Recommended practical approach: cardiomyopathy gene panel including **MYBPC3**; consider exome/genome in unresolved or syndromic/early severe cases | Genetic testing is most useful for diagnosis clarification, family screening, and differential diagnosis rather than proving morphology alone is pathologic | — | (pqac-00000018, pqac-00000019, pqac-00000013) |
| Differential diagnosis | Distinguish LVNC10 from HCM/DCM with secondary hypertrabeculation, athlete’s heart, pregnancy-related trabeculation, anemia/sickle-cell-associated trabeculation, congenital heart disease, and syndromic cardiomyopathy | ESC 2023 explicitly frames LV non-compaction as a trait that can occur in many settings | — | (pqac-00000018, pqac-00000020, pqac-00000016) |
| Prognosis | No LVNC10-specific survival estimate identified | Prognosis in LVNC depends more on ventricular dysfunction, arrhythmia burden, fibrosis/genotype context than trabeculation extent alone; LVNC cohort had more cardiovascular events than age-matched nonischemic DCM in one study | HPO suggestions: Sudden cardiac death; Thromboembolism | (pqac-00000003, pqac-00000020, pqac-00000021) |
| Treatment categories | No LVNC10 genotype-specific approved therapy identified | Treat according to phenotype: guideline-directed heart failure therapy, arrhythmia surveillance/management, anticoagulation when indicated, ICD/CRT in selected patients, transplant in end-stage disease | NCIT suggestions: Heart Failure Therapy; Anticoagulation Therapy; Implantable Cardioverter-Defibrillator; Cardiac Resynchronization Therapy; Heart Transplantation | (pqac-00000000, pqac-00000008, pqac-00000013) |
| Prevention / screening | **Cascade family screening** and genetic counseling are relevant for MYBPC3-related disease | Registry studies are actively evaluating mutation status, strain, PVC burden, NSVT, and ICD outcomes in LVNC | — | (pqac-00000013, pqac-00000018) |
| Real-world implementation | No LVNC10-specific interventional trial identified | Active observational registry: **NCT06024759** (recruiting; target n=500) studying genetics, LV strain, PVC burden, NSVT, ICD predictors; broader nonischemic cardiomyopathy registry **NCT06607471** also includes LVNC | NCT terms may be mapped separately in a trial table | (pqac-00000013, pqac-00000012) |
| Evidence gaps | No retrieved LVNC10-specific prevalence/incidence, penetrance estimate, protective variants, environmental triggers, epigenomic signature, single-cell/spatial profile, validated biomarker, or targeted MYBPC3-LVNC therapy | Broad LVNC evidence is heterogeneous and often confounded by phenocopies and imaging overdiagnosis | — | (pqac-00000018, pqac-00000020) |


*Table: This table summarizes subtype-specific facts for Left Ventricular Noncompaction 10 alongside broader LVNC context needed for interpretation. It is designed as a compact curation aid for identifiers, mechanisms, phenotypes, diagnostics, treatment categories, and major evidence gaps.*